ERBB2 and cancer: Additionally, cancer treatments—such as radiotherapy to the left chest and systemic therapies, including anthracycline-based chemotherapy and targeted treatments like Human Epidermal Growth Factor Receptor 2 (HER2) inhibitors—can lead to cancer therapy-related cardiovascular toxicity (CTR-CVT) [9, 10].